Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination

Ann Hematol. 2022 Apr;101(4):885-887. doi: 10.1007/s00277-021-04666-x. Epub 2021 Oct 1.

Authors

Kei Saito^{1

2}, Satoshi Ichikawa³, Shunsuke Hatta^{1

2}, Yuna Katsuoka¹, Hideo Harigae², Tohru Izumi¹

Affiliations

¹ Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
² Department of Hematology, Tohoku University Hospital, Sendai, Japan.
³ Department of Hematology, Tohoku University Hospital, Sendai, Japan. [email protected].

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Purpura, Thrombocytopenic, Idiopathic* / etiology
SARS-CoV-2
Vaccination
Vincristine

Substances

COVID-19 Vaccines
Vincristine